KMTS (Kestra Medical Technologies) Cash Conversion Cycle: -76.46 (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KMTS Kestra Medical Technologies Ltd KMTS
10 GF Score
Price $24.24
! 4 Warning Signs
View Full Analysis

What is Kestra Medical Technologies Cash Conversion Cycle?

Kestra Medical Technologies KMTS -2.34% 10 Cash Conversion Cycle is -76.46 as of Jan. 2026. GuruFocus rates KMTS with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Kestra Medical Technologies's Days Sales Outstanding for the three months ended in Jan. 2026 was 42.97.
Kestra Medical Technologies's Days Inventory for the three months ended in Jan. 2026 was 53.86.
Kestra Medical Technologies's Days Payable for the three months ended in Jan. 2026 was 173.29.
Therefore, Kestra Medical Technologies's Cash Conversion Cycle (CCC) for the three months ended in Jan. 2026 was -76.46.


Kestra Medical Technologies  (NAS:KMTS) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Kestra Medical Technologies Cash Conversion Cycle Related Terms


Kestra Medical Technologies Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Kestra Medical Technologies's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kestra Medical Technologies Cash Conversion Cycle Chart

Kestra Medical Technologies Annual Data
Trend Apr20 Apr21 Apr23 Apr24
Cash Conversion Cycle
0.00 0.00 -36.29 -137.66

Kestra Medical Technologies Quarterly Data
Apr20 Jul20 Apr21 Jul21 Apr23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -149.48 -133.68 -85.65 -62.87 -76.46

KMTS vs ATRC, STAA, BLFS: Cash Conversion Cycle Comparison

For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kestra Medical Technologies Cash Conversion Cycle vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Kestra Medical Technologies's Cash Conversion Cycle falls into.


KMTS
10GF Score
Kestra Medical Technologies Ltd KMTS
Cash Conversion Cycle is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kestra Medical Technologies Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Kestra Medical Technologies's Cash Conversion Cycle for the fiscal year that ended in Apr. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=26.22+35.92-199.8
=-137.66

Kestra Medical Technologies's Cash Conversion Cycle for the quarter that ended in Jan. 2026 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=42.97+53.86-173.29
=-76.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of -76.46 mean?
Kestra Medical Technologies (KMTS) has a Cash Conversion Cycle of -76.46 as of Jan. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Kestra Medical Technologies and its competitors.
Is Kestra Medical Technologies' Cash Conversion Cycle too high?
Kestra Medical Technologies' current Cash Conversion Cycle is -76.46. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Cash Conversion Cycle compare to ATRC and STAA?
Kestra Medical Technologies' Cash Conversion Cycle of -76.46 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 157.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 157.71, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Kestra Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 157.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current Cash Conversion Cycle is -76.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Cash Conversion Cycle of -76.46. The current Cash Conversion Cycle is -76.46. Kestra Medical Technologies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Cash Conversion Cycle is -76.46 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kestra Medical Technologies Business Description

Address 3933 Lake Washington Boulevard NE, Suite 200, Kirkland, WA, USA, 98033
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score

Get the complete analysis for KMTS

Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.24
Price